Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Kissei Pharmaceutical CoKSPHF -4.45%78 Earnings Yield (Joel Greenblatt) % is 12.00% as of Mar. 2026, which is 3% below its 10-year median of 12.37. GuruFocus rates KSPHF with a GF Score™ of 78/100 and a GF Value™ of $28.99. The stock has 1 warning sign investors should review. Among 1,007 Drug Manufacturers companies, Kissei Pharmaceutical Co ranks better than 88.88% on this metric.
Kissei Pharmaceutical Co's Enterprise Value for the quarter that ended in Mar. 2026 was $741.9 Mil.
Kissei Pharmaceutical Co's EBIT for the trailing twelve months (TTM) ended in Mar. 2026 was $111.7 Mil. Kissei Pharmaceutical Co's Earnings Yield (Joel Greenblatt) for the quarter that ended in Mar. 2026 was 12.00%.
The historical rank and industry rank for Kissei Pharmaceutical Co's Earnings Yield (Joel Greenblatt) % or its related term are showing as below:
KSPHF'
s Earnings Yield (Joel Greenblatt) % Range Over the Past 10 Years
Min: 5.61 Med: 12.37 Max: 27.98
Current: 14.27
During the past 13 years, the highest Earnings Yield (Joel Greenblatt) of Kissei Pharmaceutical Co was 27.98%. The lowest was 5.61%. And the median was 12.37%.
KSPHF's Earnings Yield (Joel Greenblatt) % is ranked better than 88.88% of 1007
companies
in the Drug Manufacturers industry
Industry Median: 3.25
vs KSPHF: 14.27
Joel Greenblatt's definition of earnings yield has the same problems the regular earnings yield does. It does not consider the growth of the company. It only looks at one-year's business operation. For cyclical companies, the earnings yield is usually highest at the peak of the business cycle. But these earnings are rarely sustainable.
A better indicator of the attractiveness of an investment which takes growth into account is the Forward Rate of Return (Yacktman) %. Kissei Pharmaceutical Co's Forward Rate of Return (Yacktman) % for the quarter that ended in Mar. 2026 was 11.38%. The Forward Rate of Return uses the normalized Free Cash Flow of the past five years, and considers growth. The forward rate of return can be thought of as the return that investors buying the stock today can expect from it in the future.
Kissei Pharmaceutical Co (OTCPK:KSPHF) Earnings Yield (Joel Greenblatt) % Explanation
Joel Greenblatt defines the earnings yield using the above equation because it more accurately reflects the company's profitability relative to its stock price. Items like interest payment and tax etc. are not directly related to the company's operational profitability.
Enterprise Value instead of market cap (share price) is used in the calculation because it is the real price stock and bond investors together pay for the company.
Be Aware
Joel Greenblatt's definition of earnings yield has the same problems the regular earnings yield does. It does not consider the growth of the company. It only looks at one-year's business operation. For cyclical companies, the earnings yield is usually highest at the peak of the business cycle. But these earnings are rarely sustainable.
Kissei Pharmaceutical Co Earnings Yield (Joel Greenblatt) % Related Terms
Kissei Pharmaceutical Co Earnings Yield (Joel Greenblatt) % Historical Data
* Premium members only.
The historical data trend for Kissei Pharmaceutical Co's Earnings Yield (Joel Greenblatt) % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Kissei Pharmaceutical Co Earnings Yield (Joel Greenblatt) % Chart
KSPHF vs ZTS: Earnings Yield (Joel Greenblatt) % Comparison
For the Drug Manufacturers - Specialty & Generic subindustry, Kissei Pharmaceutical Co's Earnings Yield (Joel Greenblatt) %, along with its competitors' market caps and Earnings Yield (Joel Greenblatt) % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Kissei Pharmaceutical Co Earnings Yield (Joel Greenblatt) % vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Kissei Pharmaceutical Co's Earnings Yield (Joel Greenblatt) % distribution charts can be found below:
* The bar in red indicates where Kissei Pharmaceutical Co's Earnings Yield (Joel Greenblatt) % falls into.
Kissei Pharmaceutical Co Earnings Yield (Joel Greenblatt) % Calculation
In his book, The Little That Beat the Market, hedge fund manager Joel Greenblatt defines Earnings Yield as operating income divided by enterprise value.
Kissei Pharmaceutical Cos Earnings Yield (Joel Greenblatt) for the fiscal year that ended in Mar. 2026 is calculated as
Kissei Pharmaceutical Co's EBIT for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $111.7 Mil.
What does a Earnings Yield (Joel Greenblatt) % of 12.00% mean?
Kissei Pharmaceutical Co (KSPHF) has a Earnings Yield (Joel Greenblatt) % of 12.00% as of Mar. 2026. Joel Greenblatt's earnings yield equals the ratio of earnings before interest and taxes to enterprise value. View historical data on Kissei Pharmaceutical Co and its competitors. This is near median its historical median of 12.37. Over the past decade, Kissei Pharmaceutical Co's Earnings Yield (Joel Greenblatt) % has ranged from 5.61 to 27.98. According to the industry distribution chart, Kissei Pharmaceutical Co ranks #112 out of 1007 companies in the Drug Manufacturers industry, placing it in the top 11.1%.
Is Kissei Pharmaceutical Co's Earnings Yield (Joel Greenblatt) % too high?
Kissei Pharmaceutical Co's current Earnings Yield (Joel Greenblatt) % of 12.00% is near median its 10-year median of 12.37. Over the past 10 years, this metric has ranged from a low of 5.61 to a high of 27.98. The Drug Manufacturers industry median Earnings Yield (Joel Greenblatt) % is 3.25. Kissei Pharmaceutical Co's value of 12.00% is 269.2% above this industry median. Based on the distribution chart, Kissei Pharmaceutical Co ranks #112 out of 1007 companies in the Drug Manufacturers industry, which is in the top quartile — a strong position relative to peers. Overall, Kissei Pharmaceutical Co has a GF Score™ of 78/100, reflecting its overall financial health beyond just this single metric.
How does Kissei Pharmaceutical Co's Earnings Yield (Joel Greenblatt) % compare to ZTS?
According to the Drug Manufacturers industry distribution chart, Kissei Pharmaceutical Co ranks #112 out of 1007 companies for Earnings Yield (Joel Greenblatt) %. This places Kissei Pharmaceutical Co in the top 11% of its industry — outperforming the majority of peers. The industry median Earnings Yield (Joel Greenblatt) % is 3.25. Kissei Pharmaceutical Co's value of 12.00% is 269.2% above this benchmark. Historically, Kissei Pharmaceutical Co's own Earnings Yield (Joel Greenblatt) % has ranged from 5.61 to 27.98 over the past decade. While the company's 10-year median is 12.37 vs. the industry median of 3.25, Kissei Pharmaceutical Co has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Earnings Yield (Joel Greenblatt) % for a Drug Manufacturers company?
The median Earnings Yield (Joel Greenblatt) % among Drug Manufacturers companies is 3.25, based on 1,007 companies in the industry. Companies in the top quartile (top 25%) have a Earnings Yield (Joel Greenblatt) % significantly above this median, while those in the bottom quartile fall well below. However, Earnings Yield (Joel Greenblatt) % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Kissei Pharmaceutical Co's current Earnings Yield (Joel Greenblatt) % of 12.00% is 269.2% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Earnings Yield (Joel Greenblatt) % mean?
A high Earnings Yield (Joel Greenblatt) % can signal that a stock is expensive relative to its fundamentals. Joel Greenblatt's earnings yield equals the ratio of earnings before interest and taxes to enterprise value. View historical data on Kissei Pharmaceutical Co and its competitors. For the Drug Manufacturers industry, the median Earnings Yield (Joel Greenblatt) % is 3.25 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Kissei Pharmaceutical Co's current Earnings Yield (Joel Greenblatt) % is 12.00%, which is near median its own 10-year median of 12.37. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Kissei Pharmaceutical Co stock overvalued right now?
Kissei Pharmaceutical Co (KSPHF) has a current Earnings Yield (Joel Greenblatt) % of 12.00%. The stock's GF Value™ is $28.99, compared to a current price of $25.77 — trading 11.1% below its estimated fair value. The current Earnings Yield (Joel Greenblatt) % is 12.00%, which is near median its 10-year median of 12.37 and 269.2% above the Drug Manufacturers industry median of 3.25. Kissei Pharmaceutical Co's overall GF Score™ is 78/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Earnings Yield (Joel Greenblatt) % calculated?
Earnings Yield (Joel Greenblatt) % is calculated from a company's financial statements. For Kissei Pharmaceutical Co (KSPHF), the current Earnings Yield (Joel Greenblatt) % is 12.00% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Kissei Pharmaceutical Co (KSPHF) Overvalued in 2026?
Based on GuruFocus' analysis, Kissei Pharmaceutical Co stock appears to be undervalued.
The current stock price of $25.77 is trading 11.1% below its estimated GF Value™ of $28.99.
Key valuation signals for KSPHF:
Earnings Yield (Joel Greenblatt) %: 12.00% (near median its 10-year median of 12.37)
GF Value™: $28.99 vs. price of $25.77 (11.1% below fair value)
Industry Position: 269.2% above the Drug Manufacturers median (#112 of 1007)
No single metric tells the full story. See the KSPHF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Kissei Pharmaceutical Co Ltd is a specialty and generic drug manufacturing company. Pharmaceuticals is the company's reportable segment. The company's operations span across the globe, while the vast majority of revenue is generated in Japan, followed by Europe. Kissei operates a variety of subsidiaries. The company considers merger and acquisition investment as a potential component of its operational growth strategy for expanding its research, development, manufacturing, and marketing capabilities.
78GF Score
Get the complete analysis for KSPHF
Earnings Yield (Joel Greenblatt) % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
KSPHF has been successfully added to your 
